Targeted Therapy With Immunoconjugates for Multiple Myeloma
Frontiers in Immunology, 2020 The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated monoclonal antibodies (mAb) daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7)
Sonja Zweegman, Tuna Mutis
exaly +4 more sources
Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering? [PDF]
Frontiers in Pharmacology, 2022 Immune checkpoint mechanisms are important molecular cell systems that maintain tolerance toward autoantigens in order to prevent immunity-mediated accidental damage.
Andrea Bolognesi +2 more
exaly +4 more sources
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. [PDF]
PLoS ONE, 2012 BACKGROUND: Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate the latent reservoir of HIV infection using activate-and-purge protocols.
Ryan B Craig +3 more
doaj +2 more sources
Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
Hemato, 2021 In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care in ...
Wassilis Sc Bruins, Sonja Zweegman
exaly +3 more sources
Ribosome-Inactivating Proteins from Salsola soda L. and Saponaria officinalis L. Are Promising Candidates for Targeted Therapy of Colon Cancer [PDF]
BiomedicinesBackground/Objectives: Ribosome-inactivating proteins (RIPs) are plant-derived enzymes with potent cytotoxic activity, widely studied as anticancer agents, particularly as toxic payloads in immunoconjugates. Despite numerous encouraging results reported,
Francesco Biscotti +8 more
doaj +2 more sources
Antibodies, 2018 Accumulating evidence suggests that tissue factor (TF) is selectively expressed in pathological angiogenesis-dependent as well as macrophage-associated human diseases.
Zhiwei Hu
exaly +3 more sources
A novel strategy for treatment of bladder cancer: Antibody-drug conjugates [PDF]
Investigative and Clinical Urology, 2022 In the past, there was no second-line chemotherapeutic agent suitable for use when urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several new treatment options, such as immune checkpoint inhibitors or targeted therapy ...
Jung Hoon Kim, In Ho Chang
doaj +1 more source
Antibody Conjugates for Sarcoma Therapy: How Far along Are We?
Biomedicines, 2021 Sarcomas are one of the most difficult type of cancer to manage and treat because of their extremely heterogeneous molecular and morphological features. Despite the progress made over the years in the establishment of standard protocols for high and low ...
Letizia Polito +5 more
doaj +1 more source
Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity [PDF]
Iranian Journal of Immunology, 2023 Background: Trastuzumab is a humanized monoclonal antibody that targets site-specifically human epidermal growth factor-2 receptor (HER2) cell surface antigen overexpressed in approximately 20% of human breast carcinomas. Despite its positive therapeutic
Soodabeh Shafiee +5 more
doaj +1 more source
Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
Frontiers in Immunology, 2021 Although advances in antiretroviral therapy (ART) have significantly improved the life expectancy of people living with HIV-1 (PLWH) by suppressing HIV-1 replication, a cure for HIV/AIDS remains elusive.
Jeffrey C. Umotoy, Steven W. de Taeye
doaj +1 more source